MNK

Mallinckrodt PLC

Healthcare


Presented:11/19/2015
Price:$60.08
Cap:$7.08B
Current Price:no data
Cap:no data

Presented

Date11/19/2015
Price$60.08
Market Cap$7.08B
Ent Value$18.89B
P/E RatioN/A
Book Value$45.18
Div Yield0%
Shares O/S117.80M
Ave Daily Vol3,393,636
Short Int8.76%

Current

Priceno data
Market Capno data
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment produces and markets branded pharmaceuticals and biopharmaceuticals, specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems and radiopharmaceuticals. Mallinckrodt was founded on January 9, 2013 and is headquartered in Dublin, Ireland.

Publicly traded companies mentioned herein: Allergan (AGN), ANI Pharmaceuticals Inc (ANIP), Mallinckrodt PLC (MNK), Merck & Co Inc (MRK), Mylan NV (MYL), Teva Pharmaceuticals Industries (TEVA)

Highlights

Mallinckrodt (MNK) is one of the more controversial names in the specialty pharmaceutical space, and the presenter said he has been using the recent weakness in the stock price to build a long position. With shares trading at ~$60 he sees a favorable risk/ reward for bulls, as the nearly perfect negative storm of news impacting specialty pharmaceuticals companies should pass. He noted that from late 2009 to 2011 he performed a substantial amount of due diligence on Questcor (and its H.P. Acthar Gel), and was fortunate to be long the stock heading into its acquisition by MNK in 2014. Having “a good handle on the fundamentals” gives the presenter confidence in his position, and in a more “sane” environment he thinks the stock is worth $90/share.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.